Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

NCT00009880 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of combination chemotherapy plus radiation therapy with and without fluorouracil in treating patients who have cancer of the esophagus or stomach.

Interventions

  • DRUG cisplatin
  • DRUG paclitaxel
  • DRUG fluorouracil
  • RADIATION radiation therapy
  • BIOLOGICAL filgrastim

Study Locations (20)

Indiana

  • Indiana University Cancer Center — Indianapolis
  • Veterans Affairs Medical Center - Indianapolis (Roudebush) — Indianapolis
  • Cancer Center at Ball Memorial Hospital — Muncie
  • Memorial Hospital of South Bend — South Bend
  • Union Hospital — Terre Haute

Florida

  • University of Florida Shands Cancer Center — Gainesville
  • Baptist-South Miami Regional Cancer Program — Miami
  • CCOP - Mount Sinai Medical Center — Miami Beach

California

  • City of Hope Comprehensive Cancer Center — Duarte
  • Leavey Cancer Center at Northridge Hospital Medical Center — Northridge

Alabama

  • Mobile Infirmary Medical Center — Mobile

Arizona

  • Foundation for Cancer Research and Education — Phoenix

Hawaii

  • Cancer Research Center of Hawaii — Honolulu

Illinois

  • Methodist Medical Center of Illinois — Peoria

Iowa

  • Wendt Regional Cancer Center at Finley Hospital — Dubuque

Trial Details

FieldValue
Start Date 2001-04
Phase Phase 2

Sponsor

Radiation Therapy Oncology Group

37 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00009880

The ClinicalTrials.gov registry entry for NCT00009880 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Radiation Therapy Oncology Group, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions — of which cisplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00009880 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Indiana, Florida, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00009880 about?

NCT00009880 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Randomized phase II trial to comp...

What is the current status of trial NCT00009880?

This trial is currently completed. It is a Phase 2 study. The study started on 2001-04.

What conditions does trial NCT00009880 study?

This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00009880?

The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), fluorouracil (DRUG), radiation therapy (RADIATION), filgrastim (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00009880?

This trial is sponsored by Radiation Therapy Oncology Group, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00009880 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial